AI
ITCI

AdvisorShares Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AdvisorShares Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,077
Closed -$406K – 340
2025
Q1 		$406K Sell
3,077
-186
-6% -$23.2K 0.08% 174
2024
Q4 		$273K Buy
3,263
+458
+16% +$37.6K 0.05% 205
2024
Q3 		$205K Sell
2,805
-900
-24% -$67.6K 0.04% 217
2024
Q2 		$252K Sell
3,705
-870
-19% -$60.3K 0.04% 214
2024
Q1 		$317K Buy
4,575
+424
+10% +$29.1K 0.05% 208
2023
Q4 		$297K Sell
4,151
-1,621
-28% -$93.2K 0.07% 207
2023
Q3 		$301K Buy
5,772
+1,057
+22% +$61.6K 0.08% 174
2023
Q2 		$299K Sell
4,715
-115
-2% -$7.17K 0.09% 179
2023
Q1 		$262K Sell
4,830
-399
-8% -$19.3K 0.08% 176
2022
Q4 		$277K Sell
5,229
-2,847
-35% -$143K 0.08% 200
2022
Q3 		$376K Buy
+8,076
New +$422K 0.1% 193

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AdvisorShares Investments's ITCI Position: Q2 2025 in Review

AdvisorShares Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,077 shares — an estimated $406K sold.

AdvisorShares Investments first reported a position in ITCI in Q3 2022 and held it in 11 quarters. The position peaked at $406K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • AdvisorShares Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • AdvisorShares Investments sold 3,077 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $406K.
  • AdvisorShares Investments first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 11 quarters.
  • AdvisorShares Investments's Intra-Cellular Therapies Inc. position peaked at $406K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on AdvisorShares Investments's 13F filing for Q2 2025, filed 4 Aug 2025.